Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

(2014) Jeffrey L. Lennox et al.   ANNALS OF INTERNAL MEDICINE

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial

(2014) JE Lake et al.   HIV MEDICINE

Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non–AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment

(2014) Allan R. Tenorio et al.   JOURNAL OF INFECTIOUS DISEASES

Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection

(2014) Peter W. Hunt et al.   JOURNAL OF INFECTIOUS DISEASES

A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events

(2014) Akintunde O. Akinkuolie et al.   Journal of the American Heart Association

Differential penetration of raltegravir throughout gastrointestinal tissue

(2013) Kristine B. Patterson et al.   AIDS

Effects of Switching From Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function

(2013) Samir K. Gupta et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Body Composition, Soluble Markers of Inflammation, and Bone Mineral Density in Antiretroviral Therapy–Naive HIV-1–Infected Individuals

(2013) Todd T. Brown et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Increase in 2–Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial

(2013) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

(2012) Grace A. McComsey et al.   AIDS

Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens

(2012) David M. Asmuth et al.   AIDS

Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery

(2012) Marta Massanella et al.   AIDS

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

(2012) Esteban Martínez et al.   AIDS

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients

(2012) Alejandro Vallejo et al.   AIDS

A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis

(2012) Karim Sacre et al.   AIDS

Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection

(2012) James H. Stein et al.   AIDS

Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome

(2012) N. T. Funderburg et al.   BLOOD

Biomarkers of Microbial Translocation and Macrophage Activation: Association With Progression of Subclinical Atherosclerosis in HIV-1 Infection

(2012) Theodoros Kelesidis et al.   JOURNAL OF INFECTIOUS DISEASES

Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals

(2012) Daniel A. Duprez et al.   PLoS One

Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes

(2011) Fernanda Scopelliti et al.   ANTIVIRAL RESEARCH

Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients

(2011) Tricia H. Burdo et al.   JOURNAL OF INFECTIOUS DISEASES

A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response

(2011) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

Higher Levels of CRP, D-dimer, IL-6, and Hyaluronic Acid Before Initiation of Antiretroviral Therapy (ART) Are Associated With Increased Risk of AIDS or Death

(2011) David R. Boulware et al.   JOURNAL OF INFECTIOUS DISEASES

Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection

(2011) Netanya G. Sandler et al.   JOURNAL OF INFECTIOUS DISEASES

Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy

(2010) T. T. Brown et al.   DIABETES CARE

Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection

(2010) Jason V Baker et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection

(2010) Jacqueline Neuhaus et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Monocytes in atherosclerosis: subsets and functions

(2010) Kevin J. Woollard et al.   Nature Reviews Cardiology

Raltegravir: The First HIV Type 1 Integrase Inhibitor

(2009) Charles Hicks et al.   CLINICAL INFECTIOUS DISEASES

Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction

(2009) Virginia A Triant et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection

(2008) Lewis H Kuller et al.   PLOS MEDICINE

HIV infection and high density lipoprotein metabolism

(2007) Honor Rose et al.   ATHEROSCLEROSIS